Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several mechanistic and drug-class claims are supported, and hyperkalemia as an adverse reaction is supported. However, the primary indication claim is only partially supported by the provided label text (notably inclusion of 'stroke'), while hypotension and fatigue are unsupported and pricing is absent from the label.
Category Scores
Accurate Statements
Kerendia is a non-steroidal mineralocorticoid receptor antagonist.
Supported by Section 11 DESCRIPTION and/or Section 12.1 Mechanism of Action.
Kerendia works by blocking the harmful effects of excess mineralocorticoid receptor (MR) activity.
Supported by Section 12.1 Mechanism of Action (Finerenone blocks MR-mediated sodium reabsorption and MR overactivation; MR overactivation thought to contribute to fibrosis/inflammation).
Common side effects of Kerendia include hyperkalemia (high potassium levels).
Hyperkalemia is discussed in Section 5.1 Hyperkalemia and referenced as a serious adverse reaction in Section 6.
Unsupported Statements
Excess mineralocorticoid receptor (MR) activity is implicated in the progression of chronic kidney disease and cardiovascular disease in patients with type 2 diabetes.
Not explicitly stated in the provided label text; Section 12.1 discusses MR overactivation contributing to fibrosis/inflammation but does not include the specific phrasing about progression of CKD/CVD in T2DM.
Common side effects of Kerendia include hypotension (low blood pressure).
Hypotension is not mentioned in the provided label sections.
Common side effects of Kerendia include fatigue.
Fatigue is not mentioned in the provided label sections.
As of late 2023, reported prices for a 30-day supply of Kerendia (20 mg once daily) in the United States can range from approximately $550 to over $600 before any discounts or insurance.
Pricing/cost information is not present in the provided FDA label sections.
Contradictions
Low
AI Statement
Kerendia (finerenone) is used to reduce the risk of sustained decline in kidney function, kidney failure, cardiovascular death, non-fatal heart attacks, and stroke in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes.
Label Reference
Section 1 INDICATIONS AND USAGE (provided text supports reducing risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization/urgent HF visits; 'stroke' is not included in the shown indication language).
Important Omissions
The indication claim should not omit or incorrectly add endpoints relative to the labeled indication language (e.g., 'stroke' is not shown in the provided Section 1 excerpt; 'hospitalization for heart failure' and related outcomes are shown).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The main safety-related concern from label mismatch is an indication endpoint overstatement ('stroke' not shown in provided label text). Additional unsupported adverse-reaction claims (hypotension, fatigue) could mislead expectations, though hyperkalemia support is correct.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Indication claim includes 'stroke,' which is not supported by the provided Section 1 indication text excerpt; other adverse-reaction and pricing claims are unsupported by the provided label sections.
Suggested Improvement
Align the indication endpoints exactly to the provided Section 1 wording (remove 'stroke' unless supported elsewhere in the label not provided; include labeled heart failure outcomes if relevant). Remove or revise unsupported 'hypotension' and 'fatigue' adverse-reaction claims, and exclude pricing information because it is not present in the provided FDA label sections.